Nektar Therapeutics NKTR

Nektar Therapeutics stock took a hit Thursday despite test results that suggested its drug has long-term benefits for alopecia patients.

Nektar Therapeutics reports sustained hair regrowth after treatment ended, while analysts see positive implications for a competing drug.

Nektar Therapeutics (NASDAQ:NKTR) presented new clinical and biomarker findings for rezpegaldesleukin, or REZPEG, at the EADV 2026 Congress, highlighting six-month off-treatment results in severe to very severe alopecia areata and molecular findings from its Phase IIb atopic dermatitis program. REZ

NKTR, QSI, and PACB are drawing attention from options bears

Nektar Therapeutics (Nasdaq: NKTR) today announced that long-term data on rezpegaldesleukin from the Phase 2b REZOLVE-AA and Phase 2b REZOLVE-AD studies are being presented at the European Academy of Dermatology and Venereology (EADV) Congress 2026 in Vienna, Austria in two oral presentation sessions.

Nektar Therapeutics (Nasdaq: NKTR) and collaborators at the Icahn School of Medicine at Mount Sinai today announced new results from a multi-omic biomarker sub-study from REZOLVE-AD providing further evidence that rezpegaldesleukin engages its regulatory Tcell (Treg)-mediated mechanism in patients with moderate-to-severe atopic dermatitis, with significant biomarker changes associated with clinical improvement observed as early as Week 2.

Nektar Therapeutics recently announced that data from its Phase 2b rezpegaldesleukin trials in atopic dermatitis and alopecia areata were presented in three oral sessions at the 2026 EADV Congress in Vienna, including new 6‑month off‑treatment results in severe alopecia areata and maintenance data in atopic dermatitis. The inclusion of late‑breaking multi‑omic findings from the REZOLVE‑AD biomarker sub‑study adds an unusual level of mechanistic insight that could influence how investors...

Nektar Therapeutics (NasdaqCM:NKTR) plans three oral presentations on rezpegaldesleukin at the European Academy of Dermatology & Venereology Congress 2026. The talks will share 6‑month off‑treatment durability data from the Phase 2b REZOLVE-AA trial in severe alopecia areata. Multi‑omic biomarker findings from atopic dermatitis patients on rezpegaldesleukin are also scheduled for presentation at EADV 2026. The new rezpegaldesleukin durability and biomarker readouts come in addition to a...

Nektar Therapeutics (Nasdaq: NKTR) announced today that data from its Phase 2b studies of rezpegaldesleukin in atopic dermatitis and alopecia areata will be presented in three separate oral presentations at the European Academy of Dermatology & Venereology (EADV) Congress 2026, to take place September 30 to October 3, 2026, in Vienna, Austria.

Nektar Therapeutics (NKTR) has drawn fresh attention after recent share price swings, with the stock down 4% over the past day and 21% over the past month on available return data. At a share price of US$57.06, Nektar Therapeutics has swung sharply lower in the short term, with the 7 day share price return down 14.63% and the 30 day share price return down 21.32%. However, the year to date share price return remains up 31.41%, hinting that recent weakness follows a stronger run earlier in the...

Key Stats for LLY StockPast week’s performance: 1. 6%52-week range: $716 to $1,293Valuation model target price: $1,834Implied upside: 54.

Key Stats for Eli Lilly StockCurrent Price: $1,183. 46Target Price (Mid): ~$2,060Street Target: ~$1,325Potential Total Return: ~74%Annualized IRR: ~14% / yearWhat Happened?Eli Lilly and Company (LLY) closed essentially flat at $1,183.

Nektar Therapeutics (NASDAQ: NKTR) today announced that, on September 18, 2026, the Organization and Compensation Committee of Nektar's Board of Directors granted non-qualified stock options to purchase an aggregate of 58,600 shares of its common stock and 2,450 restricted stock units (RSUs) to eleven newly-hired employees under Nektar's 2025 Inducement Plan.

Healthcare stocks rose late Friday afternoon with the NYSE Healthcare Index increasing 0.3% and the

Healthcare stocks edged higher Friday afternoon, with the NYSE Healthcare Index and the State Street

All three major US stock indexes were edging higher in midday trading Friday as Treasury yields rema

(Updates to add Eli Lilly's response in the fifth and sixth paragraphs.) Nektar Therapeutics (NK

A federal jury in California has awarded Nektar Therapeutics Inc. (NASDAQ:NKTR) $90 million in damages, finding that Eli Lilly and Co. (NYSE:LLY) breached the implied covenant of good faith and fair dealing. Nektar Therapeutics Wins $90 Million Judgment Against Eli Lilly The lawsuit, filed in August 2023, stemmed from a previous licensing agreement between the two companies for the development and commercialization of the drug rezpegaldesleukin. Jury Finds Breach of Covenant The trial in the U.S